Research programme: ubiquitination protein degradation therapeutics - BeyondSpring Pharmaceuticals

Drug Profile

Research programme: ubiquitination protein degradation therapeutics - BeyondSpring Pharmaceuticals

Alternative Names: BPI-001

Latest Information Update: 21 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BeyondSpring Pharmaceuticals
  • Class Antineoplastics; Ligases
  • Mechanism of Action Ubiquitin protein ligase complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Aug 2018 Preclinical trials in Cancer in USA (unspecified route) (BeyondSpring Pharmaceuticals pipeline, August 2018)
  • 21 Jun 2018 BeyondSpring Pharmaceuticals plans clinical development of BPI 001 in 2019
  • 03 Apr 2018 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top